GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » Debt-to-Asset

Addex Therapeutics (XSWX:ADXN) Debt-to-Asset : 0.07 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics Debt-to-Asset?

Addex Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.27 Mil. Addex Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.07 Mil. Addex Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was CHF4.64 Mil. Addex Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.07.


Addex Therapeutics Debt-to-Asset Historical Data

The historical data trend for Addex Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Debt-to-Asset Chart

Addex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.02 0.05 0.07

Addex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.03 0.05 0.07

Competitive Comparison of Addex Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Addex Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Debt-to-Asset falls into.



Addex Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Addex Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Addex Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Addex Therapeutics  (XSWX:ADXN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Addex Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Addex Therapeutics (XSWX:ADXN) Business Description

Traded in Other Exchanges
Address
Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202
Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire 02-24-2021